News
AG-221 sparked durable responses in hematologic cancers
Key clinical point: AG-221 could shift the treatment for IDH2 mutation-positive hematologic cancers. Major finding: Fourteen of 25 patients...
News
Idelalisib efficacy remains rock steady in relapsed CLL
Major finding: Idelalisib and rituximab significantly increased progression-free survival (HR, 0.18; P less than .0001). Data source: A...
News
Palliative care at time of cancer diagnosis improves survival
Key clinical point: Palliative care delivered at the time of cancer diagnosis improves survival.Major finding: The risk of death at 1 year was...
News
ALTTO: Dual HER2 blockade offers no survival edge in adjuvant breast cancer treatment
Major finding: Disease-free survival at 4 years was 86% with trastuzumab, 88% with concurrent lapatinib plus trastuzumab, and 87% with trastuzumab...
News
Residents, postop complications linked
Major finding: Rates were significantly higher with resident participation than without for DVT (0.80% vs. 0.62%; P = .002) and PE (0.43% vs. 0.28...
News
Eltrombopag reduces bleeding in children with chronic immune thrombocytopenia
Key clinical point: Eltrombopag may soon be a treatment option for children with chronic immune thrombocytopenia. Major finding: Platelet response...
News
Lenalidomide plus R-CHOP tackles thorny DLBCL subtype
Key clinical point: DLBCL patients with the molecular subtype non-GCB may benefit from the addition of lenalidomide to R-CHOP chemotherapy.Major...
News
Azathioprine, anti-TNF monotherapy safe in IBD pregnancy
Key clinical point: Monotherapy with azathioprine and anti-TNF agents can be continued in pregnancy with IBD to maintain remission.Major finding:...
News
Azathioprine, Anti-TNF Monotherapy Safe in IBD Pregnancy
Key clinical point: Monotherapy with azathioprine and anti-TNF agents can be continued in pregnancy with IBD to maintain remission.Major finding:...
News
Pembrolizumab monotherapy posts 6.75-month PFS in stage IV NSCLC
Key clinical point: Median progression-free survival with the classic chemotherapy doublets ranged from 4.5 months to 5.3 months but reached 6.75...
News
Immunotherapy shows promise in metastatic cervical cancer
Key clinical point: Immunotherapy using adoptive T-cell therapy can induce complete remission in metastatic cervical cancer.Major finding: An...
